Trial
NCT00054834
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Non-Hodgkins Lymphoma
Intervention
hLL2 (epratuzumab)
Why stopped
lack of accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-16